menu
    • menu
    [{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"APT-1011","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"TPG Capital IP","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ TPG Capital IP"}]

    Find Clinical Drug Pipeline Developments & Deals by Ellodi Pharmaceuticals

    Menu

    Ellodi Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3)

                            Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eosinophilic Esophagitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            December 02, 2022

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Protocol for Patients With Eosinophilic Esophagitis

                            Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in clinical studies for the treatment of Eosinophilic Esophagitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            October 27, 2021

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the F...

                            Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eosinophilic Esophagitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            October 19, 2021

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellodi Pharmaceuticals Presents Phase 2b Data at ACG 2020 on the Safety and Efficacy of Maintenance Treatment ...

                            Details : All APT-1011 dose arms showed clinically meaningful and statistically significant achievement of histological remission with reduction of eosinophil counts in the esophageal mucosa, compared to placebo, at 12 weeks.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : Fluticasone Propionate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : TPG Capital IP

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Es...

                            Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            September 22, 2020

                            Lead Product(s) : Fluticasone Propionate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : TPG Capital IP

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Ellodi Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

                            Details : APT-1011 is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eosinophilic Esophagitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            February 24, 2020

                            Lead Product(s) : APT-1011

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth